Solventum (NYSE:SOLV) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Solventum from “hold” to “buy.” Other analysts also raised price targets, though the broader analyst consensus remains “Hold” with a $91.64 target.
• Solventum exceeded second-quarter expectations, reporting $2.55 in EPS versus the $1.91 estimate and $2.21 billion in revenue versus $2.15 billion expected. Management set fiscal 2026 EPS guidance at $7.10–$7.20.
• The planned separation of its health information systems business could sharpen Solventum’s focus and unlock value, while increased institutional holdings and stronger analyst conviction provide additional investor support.

Solventum (NYSE:SOLV - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

Other analysts have also recently issued research reports about the company. Mizuho set a $113.00 price target on Solventum in a report on Thursday. Weiss Ratings upgraded shares of Solventum from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, July 17th. BTIG Research upped their price objective on shares of Solventum from $91.00 to $95.00 and gave the stock a "buy" rating in a research report on Thursday. Piper Sandler raised their target price on shares of Solventum from $92.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday. Finally, KeyCorp lifted their target price on shares of Solventum from $93.00 to $102.00 and gave the company an "overweight" rating in a research report on Thursday. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $91.64.

Solventum Trading Up 0.0%

Solventum stock opened at $83.00 on Friday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.75 and a current ratio of 1.02. Solventum has a fifty-two week low of $62.38 and a fifty-two week high of $90.00. The stock has a market cap of $14.13 billion, a P/E ratio of 10.15, a PEG ratio of 1.18 and a beta of 0.60. The firm's fifty day moving average price is $79.40 and its 200-day moving average price is $74.44.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same quarter last year, the company earned $1.69 earnings per share. The firm's quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts forecast that Solventum will post 7.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Solventum

A number of hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV increased its stake in Solventum by 52.0% in the 4th quarter. KBC Group NV now owns 462,417 shares of the company's stock worth $36,642,000 after purchasing an additional 158,242 shares during the period. US Bancorp DE boosted its stake in shares of Solventum by 4.6% during the fourth quarter. US Bancorp DE now owns 444,540 shares of the company's stock valued at $35,225,000 after purchasing an additional 19,400 shares during the period. Cambiar Investors LLC purchased a new stake in shares of Solventum during the fourth quarter valued at approximately $4,459,000. Davis Selected Advisers grew its holdings in shares of Solventum by 12.7% in the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company's stock worth $492,880,000 after purchasing an additional 702,461 shares during the last quarter. Finally, Ruffer LLP grew its holdings in shares of Solventum by 196.1% in the fourth quarter. Ruffer LLP now owns 614,558 shares of the company's stock worth $48,773,000 after purchasing an additional 407,001 shares during the last quarter.

Key Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q2 results exceeded expectations. Solventum reported adjusted earnings of $2.55 per share versus the $1.91 consensus estimate, while revenue of $2.21 billion also topped forecasts. Organic sales increased 9.5%, and revenue grew 2.2% year over year. Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
• Positive Sentiment: Management raised 2026 earnings guidance to $7.10-$7.20 per share, above its previous outlook. Strong cash flow and the company’s share-repurchase activity further support investor sentiment, although some of the quarter’s benefit came from ERP implementation timing. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: Analyst conviction strengthened. Piper Sandler raised its target to $105 and maintained an overweight rating; Wedbush lifted its target to $101 with an outperform rating; and Stifel increased its target to $100 with a buy rating. UBS also reiterated its buy recommendation. UBS Remains a Buy on Solventum Corporation
• Positive Sentiment: Software separation could sharpen the company’s focus. Solventum plans to separate its health information systems business, potentially creating a more focused medical-technology company and unlocking value from the remaining operations. Solventum to hive off healthcare software business

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source